Organization

The Pillar Biosciences leadership team consists of an experienced team developing and launching precision NGS panels accessible to the clinical oncology laboratory.

Leadership Team

Gang Song PhD Founder & Chief Executive Officer

Dr. Gang Song is a genomics innovator and co-founder of Pillar Biosciences, who co-invented Pillar Biosciences’ SLIMamp™ technology. He subsequently founded Affyimmune Therapeutics, a cellular immunotherapy company.  [more]

Dr. Gang Song is a genomics innovator and co-founder of Pillar Biosciences, who co-invented Pillar Biosciences’ SLIMamp™ technology. He subsequently founded Affyimmune Therapeutics, a cellular immunotherapy company. Previously, Dr. Song was a Technical Lead at Integrated Genetics, LabCorp (previously Genzyme Genetics), and prior to that, was a Project Lead at IQuum before its acquisition by Roche Molecular Diagnostics. Dr. Song completed his postdoctoral training in Timothy Springer's lab at Harvard Medical School and received his PhD from Shanghai Medical College of Fudan University, China.

Zhaohui Wang PhD Co-founder and Chief Science Officer

Dr. Zhaohui Wang is the technology co-inventor of SLIMamp. Formerly, she was an Associate Vice President at Integrated Genetics in the genomics laboratory at Laboratory Corporation of America (previously Genzyme Genetics).  [more]

Dr. Zhaohui Wang is the technology co-inventor of SLIMamp. Formerly, she was an Associate Vice President at Integrated Genetics in the genomics laboratory at Laboratory Corporation of America (previously Genzyme Genetics). Prior to LabCorp, Dr. Wang was a group leader at IQuum (now Roche Molecular Diagnostics). Dr. Wang received her PhD in Cellular and Molecular Biology at the University of Massachusetts, Amherst and her undergraduate degree from Peking University, China.

Martin Zillmann PhD Vice President of R&D

Dr. Martin Zillmann has a long history in nucleic acid diagnostics that started with his role as Director of Assay Development at Variagenics, a pioneer in the field of personalized medicine. [more]

Dr. Martin Zillmann has a long history in nucleic acid diagnostics that started with his role as Director of Assay Development at Variagenics, a pioneer in the field of personalized medicine. Most recently, he served as Head of the Technology Office for the Process Solutions business of MilliporeSigma. Dr. Zillmann holds a PhD in Biochemistry from Rice University and received his undergraduate education from Indiana University.

Manfred Scholz PhD, MBA Head of Corporate Development

Dr. Manfred Scholz has more than 30 years of clinical diagnostics experience. His strategic and operational management experience includes serving as CEO at Prolias LLC, and President and COO at Stem Cell Preservation Technologies.  [more]

Dr. Manfred Scholz has more than 30 years of clinical diagnostics experience. His strategic and operational management experience includes serving as CEO at Prolias LLC, and President and COO at Stem Cell Preservation Technologies. He was also VP Business Development at IQuum (now Roche Molecular Diagnostics), Senior Director of Business Development at Large Scale Biology, and held various roles at Boston Biomedical Consultants and Dade Behring (now Siemens). Dr. Scholz was a research fellow at the Max-Planck Institute for Biophysics and Harvard University. He received a PhD in Physics from Goethe University in Frankfurt, Germany, and an MBA from Babson College.

Jason Tsolas MBA Senior Director of Operations

With more than 20 years of experience in planning and directing large scale life science manufacturing, Mr. Jason Tsolas was General Manager at LaunchWorks Manufacturing Lab, supplying custom manufactured products to the life science industry. [more]

With more than 20 years of experience in planning and directing large scale life science manufacturing, Mr. Jason Tsolas was General Manager at LaunchWorks Manufacturing Lab, supplying custom manufactured products to the life science industry. Previously, at Enzymatics, he grew a team implementing best practices in manufacturing. Jason spent 12 years prior in biology-based production designing and managing automated workflow and process for DNA sequencing services at Monsanto, Genome Therapeutics Corp, Agencourt Bioscience and Beckman Coulter. Jason obtained his MBA from the McCallum Graduate School of Business at Bentley University and BA in Biology from Clark University.

Brian Dugan Associate Director of Product Management

Mr. Brian Dugan has held multiple positions in both clinical and research NGS segments. Previously at QIAGEN Inc., he led NGS Strategic Marketing for the QIAseq portfolio. [more]

Mr. Brian Dugan has held multiple positions in both clinical and research NGS segments. Previously at QIAGEN Inc., he led NGS Strategic Marketing for the QIAseq portfolio; prior, he was a product manager responsible for multiple product launches across QIAGEN’s PCR and NGS products. At Personalis Inc., he developed business opportunities on the East Coast, and at EdgeBio, he launched one of the first CLIA Exome services for clinical and pharma customers in the US. Brian has a MS in Biochemistry and Molecular Biology from Georgetown University and an BS from University of Maryland, College Park.

Scientific Advisory Board

Cheng-Zhong Zhang PhD Cofounder and Advisory Board Member

Cheng-Zhong combines single cell genomics and cell biology to study genome evolution and phenotypic variation in cancer cells. [more]

Cheng-Zhong combines single cell genomics and cell biology to study genome evolution and phenotypic variation in cancer cells. Previously he was a postdoctoral fellow working on single-molecule biophysics at Harvard Medical School (Timothy Springer's Lab) and subsequently worked on single cell genomics and cancer cell biology at Broad Institute and Dana-Farber Cancer Institute (Matthew Meyerson's Lab). He holds a PhD in Chemical Engineering with a minor in Physics from Caltech.

Timothy Springer PhD Professor, Harvard Medical School

Immunologist best known for pioneering work in discovery of the first integrins and intercellular adhesion molecules (ICAMs) and their function in the immune system. [more]

Immunologist best known for pioneering work in discovery of the first integrins and intercellular adhesion molecules (ICAMs) and their function in the immune system. Additional research interest has expanded to include malaria, transforming growth factor beta (TGF-β) signaling molecules, and von Willebrand factor. A member of the National Academy of Sciences and the American Academy of Arts and Sciences. University of California, Berkeley, a PhD in Molecular Biology and Biochemistry from Harvard University.

Paul Waring MBBS, PhD, FRCPA, FRCPath, FHGSA, FFSc(RCPA) Professor of Pathology, University of Melbourne

Paul is an anatomical, molecular and translational pathologist who is a pioneer in the application of molecular and genomic technologies to cancer diagnostics and cancer drug development. [more]

Paul is an anatomical, molecular and translational pathologist who is a pioneer in the application of molecular and genomic technologies to cancer diagnostics and cancer drug development. Previously, Paul served in various senior academic and industry positions including Director of Pathology at the Peter MacCallum Cancer Centre in Melbourne Australia, Senior Director of Pathology and Diagnostics at Genentech, USA, Chair of Pathology at the University of Melbourne, and Vice President of Medical Innovation at Roche Diagnostics USA. He has published over 140 scientific articles and abstracts, and served on numerous committees and advisory boards in the fields of cancer molecular pathology and personalized medicine. He earned an MBBS degree from the University of Western Australia, completed anatomic pathology training at the Queen Elizabeth II Medical Centre in Western Australia and a PhD in Cancer Biology from the Walter and Eliza Hall Institute at the University of Melbourne.

Marcia Eisenberg PhD Chief Science Officer and Sr. VP LabCorp

Currently oversees Research and Development, Science and Technology including test development, optimization and automation as well as Licensing and Business Development. [more]

Currently oversees Research and Development, Science and Technology including test development, optimization and automation as well as Licensing and Business Development. Marcia has developed hundreds of clinical assays used for patient care during her 25 plus years at LabCorp. She earned a BS in biology, a BA in psychology, and an MS in Molecular Biology from the State University of New York at Albany and a PhD in Molecular Biology from the University of Kentucky.

Investors

Ori Fund

A $200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally. [more]

A $200 million venture capital fund focused on investing in innovative companies with disruptive technologies in the healthcare industry globally. The fund is founded by Ms. Simone Song, former investment banker at Goldman Sachs.

Zhen Fund

A Beijing-based seed fund with a portfolio of over 150 high growth companies within technology. [more]

A Beijing-based seed fund with a portfolio of over 150 high growth companies within technology. ZhenFund was established in 2011 in collaboration with Sequoia Capital China, with the aim of promoting innovation among youth in China. After empowering Chinese students to study abroad, Bob and Victor are now dedicated to helping returnees pursue entrepreneurship in China.

Shenzhen Oriental Fortune Capital Co Ltd.

A venture capital firm specializing investment in stages from early venture to mature capital raises. [more]

A venture capital firm specializing investment in stages from early venture to mature capital raises. The firm typically invests in a broad consumer goods to telecommunications to healthcare, life sciences and pharmaceutical or biological medicine.